A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects-Reference-Cited by-同舟云学术

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Published:2020-04 Issue:4 Volume:60 Page:701-712
ISSN:0017-8748
Container-title:Headache: The Journal of Head and Face Pain
language:en
Short-container-title:Headache: The Journal of Head and Face Pain

Author:

Albrecht Detlef¹,Iwashima Mic¹,Dillon Debbie¹,Harris Stuart²,Levy Jeff²

Affiliation:

1. Satsuma Pharmaceuticals Inc. South San Francisco CA USA

2. Seaview/Quotient Miami FL USA

Funder

Satsuma Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/head.13737

Reference25 articles.

1. DHE in the Pharmacotherapy of Migraine: Potential for a Larger Role

2. Revisiting the Role of Ergots in the Treatment of Migraine and Headache

3. Dihydroergotamine: A Review of Formulation Approaches For the Acute Treatment of Migraine

4. STOP 101: A Phase 1, Randomized, Open‐Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD ® ) Device, in Healthy Adult Subjects

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine;Headache: The Journal of Head and Face Pain;2024-05-27

2. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults;Expert Review of Neurotherapeutics;2024-04-24

3. A technological comparison of freeze-dried poly-ɛ-caprolactone (PCL) and poly (lactic-co-glycolic acid) (PLGA) nanoparticles loaded with clozapine for nose-to-brain delivery;Journal of Drug Delivery Science and Technology;2024-03

4. A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults;Headache: The Journal of Head and Face Pain;2024-02-27

5. The 5-HT1B and 5-HT1D agonists in acute migraine therapy: Ergotamine, dihydroergotamine, and the triptans;Handbook of Clinical Neurology;2024